BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev 2019;51:247-65. [PMID: 31215810 DOI: 10.1080/03602532.2019.1632888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin C, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions. Clin Pharmacokinet 2020;59:781-808. [DOI: 10.1007/s40262-019-00856-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
2 Lenoir C, Rodieux F, Desmeules JA, Rollason V, Samer CF. Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review. Clin Pharmacokinet 2021;60:1537-55. [PMID: 34462878 DOI: 10.1007/s40262-021-01064-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Arrieta AC, Neely M, Day JC, Rheingold SR, Sue PK, Muller WJ, Danziger-Isakov LA, Chu J, Yildirim I, McComsey GA, Frangoul HA, Chen TK, Statler VA, Steinbach WJ, Yin DE, Hamed K, Jones ME, Lademacher C, Desai A, Micklus K, Phillips DL, Kovanda LL, Walsh TJ. Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrob Agents Chemother 2021;65:e0029021. [PMID: 34031051 DOI: 10.1128/AAC.00290-21] [Reference Citation Analysis]
4 Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol 2020;76:833-42. [PMID: 32157329 DOI: 10.1007/s00228-020-02841-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Huang F, Zhou C, Zhang XY, Shen MY, Zhang H, Wang Y, Sun L. Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies. Xenobiotica 2021;:1-8. [PMID: 34402388 DOI: 10.1080/00498254.2021.1969481] [Reference Citation Analysis]
6 Dong L, Bai N, Wang T, Cai Y. Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of voriconazole in human cerebrospinal fluid. Anal Methods 2021;13:4585-93. [PMID: 34532726 DOI: 10.1039/d1ay01103k] [Reference Citation Analysis]
7 Van Daele R, Wauters J, De Cock P, Buyle F, Leys J, Van Brantegem P, Gijsen M, Annaert P, Debaveye Y, Lagrou K, Peetermans WE, Brüggemann RJ, Spriet I. Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. Antibiotics (Basel) 2021;10:1112. [PMID: 34572694 DOI: 10.3390/antibiotics10091112] [Reference Citation Analysis]
8 Van Daele R, Bekkers B, Lindfors M, Broman LM, Schauwvlieghe A, Rijnders B, Hunfeld NGM, Juffermans NP, Taccone FS, Coimbra Sousa CA, Jacquet LM, Laterre PF, Nulens E, Grootaert V, Lyster H, Reed A, Patel B, Meersseman P, Debaveye Y, Wauters J, Vandenbriele C, Spriet I. A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms 2021;9:1543. [PMID: 34361978 DOI: 10.3390/microorganisms9071543] [Reference Citation Analysis]
9 Terrier J, Zanella MC, Masouridi-Levrat S, Kronig I, Chalandon Y, Vernaz N, Van Delden C, Papanicolaou G, Neofytos D. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. Antimicrob Agents Chemother 2021;65:e00274-21. [PMID: 33782007 DOI: 10.1128/AAC.00274-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lenoir C, Rollason V, Desmeules JA, Samer CF. Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. Front Pharmacol 2021;12:733935. [PMID: 34867341 DOI: 10.3389/fphar.2021.733935] [Reference Citation Analysis]
11 Johnson BM, Shu YZ, Zhuo X, Meanwell NA. Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. J Med Chem 2020;63:6315-86. [PMID: 32182061 DOI: 10.1021/acs.jmedchem.9b01877] [Cited by in Crossref: 82] [Cited by in F6Publishing: 53] [Article Influence: 41.0] [Reference Citation Analysis]
12 Zhang Y, Zhao S, Wang C, Zhou P, Zhai S. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization. Front Pharmacol 2021;12:636097. [PMID: 33815119 DOI: 10.3389/fphar.2021.636097] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Grensemann J, Pfaffendorf C, Wicha SG, König C, Roedl K, Jarczak D, Iwersen-Bergmann S, Manthey C, Kluge S, Fuhrmann V. Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study. Microorganisms 2021;9:2087. [PMID: 34683408 DOI: 10.3390/microorganisms9102087] [Reference Citation Analysis]
14 Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T, Miyamoto T, Egashira N, Akashi K, Ieiri I. Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Drugs R D 2021;21:419-29. [PMID: 34655050 DOI: 10.1007/s40268-021-00365-0] [Reference Citation Analysis]